Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Personalized antibody-drug conjugates: a means of tumor precision medicine

WEI Xiao-yue;ZHOU Zhan;CHEN Shu-qing;College of Pharmaceutical Sciences,Zhejiang University;  
Somatic mutation is a key factor for tumorigenesis and tumor heterogeneity,which is not fully utilized by traditional methods of malignant tumor treatment. Precision medicine means accurate diagnosis and applyment of targeted drugs to treat diseases with the help of informatics and medical technology,which based on deeply understanding of individual genomic and somatic mutation information. This is a novel model of personalized medicine,and its clinical benefits in the treatment of malignant tumors are being increasingly demonstrated. Somatic mutations endow cancer cells with specific antigens that are perfect target for antibody drugs. Personalized antibody-drug conjugates( PADCs) combine cytotoxic anticancer drugs with mutation special antibodies and are different from ordinary ADCs. PADCs target specifically to mutation antigens,without any cross-binding to normal cells. PADCs can deliver cytotoxic drugs to cancer cells specifically,achieving synergistic and attenuated effect for cancer therapy,which makes PADCs an important means of tumor precision medicine. This paper aims to outline the tumor specific antigens generated by somatic mutations,the discovery of neo-antigens,the preparation of specific antibodies and PADCs,and how PADCs kill cancer cells. The bright future of PADCs as a strategy in tumor precision medicine is described.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved